Literature DB >> 21095260

Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro.

Yan Ling1, Zhi-Yong Yang, Tao Yin, Li Li, Wei-Wei Yuan, He-Shui Wu, Chun-You Wang.   

Abstract

High-mobility group protein 1 (HMGB1) has been identified as a late-acting mediator of inflammation. The receptor for advanced glycation end products (RAGE) is the main receptor and mediates the cytokine activity of HMGB1. Since HMGB1 also exhibits heparin-binding activity, we investigated whether heparin interferes with HMGB1/RAGE interaction and prevents the cytokine activity. We used fluorescence spectrometry, circular dichroism spectrometry and SPR biosensor technique to evaluate the effect. After treatment of HMGB1 with different concentrations of heparin (0, 50, 100 and 1000 U/L), the fluorescence peak values of HMGB1 increased and the emission wavelength showed red shifts; further, the secondary structure of HMGB1 showed a marked change in that the content of β-pleated sheet reduced while that of α-helix increased. The equilibrium dissociation constants (K(D)) were determined by SPR technique; K(D)=4.5 × 10(-9)mol/L for heparin and HMGB1 and K(D)=9.77 × 10(-8)mol/L for HMGB1 and RAGE, respectively. Heparin and RAGE had no interaction. The amount of HMGB1 and RAGE bound forms reduced after treatment with heparin. ELISA revealed that addition of heparin inhibited the TNF-α and IL-6 released by macrophages RAW264.7 and HUVEC; 10 U/L and 50 U/L of heparin showed the most marked inhibitory effect in RAW264.7 cells and in HUVEC, respectively. In conclusion, heparin can combine with HMGB1 and affect the affinity of HMGB1/RAGE by changing the conformation of HMGB1. And this effect was independent of heparin concentration, so that a low dose of heparin was sufficient to achieve the best anti-inflammatory effect in our test. Crown Copyright Â
© 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21095260     DOI: 10.1016/j.intimp.2010.11.014

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  18 in total

1.  Hyperoxia, HMGB1, and ventilator-associated pneumonia: reducing risk by practicing what we teach.

Authors:  Thomas P Kennedy; Steve Nelson
Journal:  Am J Respir Cell Mol Biol       Date:  2013-03       Impact factor: 6.914

2.  2-O, 3-O Desulfated Heparin Blocks High Mobility Group Box 1 Release by Inhibition of p300 Acetyltransferase Activity.

Authors:  Shuo Zheng; Apparao B Kummarapurugu; Daniel K Afosah; Nehru Viji Sankaranarayanan; Rio S Boothello; Umesh R Desai; Thomas Kennedy; Judith A Voynow
Journal:  Am J Respir Cell Mol Biol       Date:  2017-01       Impact factor: 6.914

Review 3.  Activated Platelets and Platelet-Derived Extracellular Vesicles Mediate COVID-19-Associated Immunothrombosis.

Authors:  Marie Ebeyer-Masotta; Tanja Eichhorn; René Weiss; Lucia Lauková; Viktoria Weber
Journal:  Front Cell Dev Biol       Date:  2022-07-06

4.  Elevated levels of high-mobility group box-1 (HMGB1) in patients with severe or uncomplicated Plasmodium falciparum malaria.

Authors:  Davide Angeletti; Mpungu Steven Kiwuwa; Justus Byarugaba; Fred Kironde; Mats Wahlgren
Journal:  Am J Trop Med Hyg       Date:  2013-02-11       Impact factor: 2.345

Review 5.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

6.  Heparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage.

Authors:  J Marc Simard; Cigdem Tosun; Svetlana Ivanova; David B Kurland; Caron Hong; Leanne Radecki; Carter Gisriel; Rupal Mehta; David Schreibman; Volodymyr Gerzanich
Journal:  Transl Stroke Res       Date:  2012-04-14       Impact factor: 6.829

Review 7.  Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?

Authors:  Ulf Andersson; William Ottestad; Kevin J Tracey
Journal:  Mol Med       Date:  2020-05-07       Impact factor: 6.354

Review 8.  High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies.

Authors:  Shunling Yuan; Zhaoping Liu; Zhenru Xu; Jing Liu; Ji Zhang
Journal:  J Hematol Oncol       Date:  2020-07-13       Impact factor: 17.388

9.  The HMGB1/RAGE Pro-Inflammatory Axis in the Human Placenta: Modulating Effect of Low Molecular Weight Heparin.

Authors:  Cristian Zenerino; Anna Maria Nuzzo; Domenica Giuffrida; Marilisa Biolcati; Alessandra Zicari; Tullia Todros; Alessandro Rolfo
Journal:  Molecules       Date:  2017-11-17       Impact factor: 4.411

Review 10.  Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.

Authors:  Judith A Voynow; Shuo Zheng; Apparao B Kummarapurugu
Journal:  Front Pharmacol       Date:  2020-07-08       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.